Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 14,400 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares of the company's stock, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.44 during trading hours on Wednesday, hitting $84.23. 2,203,078 shares of the company's stock traded hands, compared to its average volume of 3,811,529. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The firm has a market capitalization of $50.70 billion, a P/E ratio of 36.50, a P/E/G ratio of 3.62 and a beta of 1.05. The business's fifty day moving average price is $90.23 and its two-hundred day moving average price is $79.16.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. DSM Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $34,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences in the first quarter worth about $34,000. Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $38,000. Finally, Operose Advisors LLC raised its stake in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock valued at $44,000 after purchasing an additional 452 shares during the period. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Mizuho lifted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a "buy" rating in a research report on Thursday, April 11th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a "neutral" rating in a report on Friday, April 26th. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research note on Friday, April 26th. Finally, Citigroup increased their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and an average price target of $92.71.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.